T. Rowe Price Associates
ZYNE

T. Rowe Price Associates’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

T. Rowe Price Associates’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,200
Closed -$14K – 3003
2022
Q3 		$14K Hold
18,200
– – ﹤0.01% 2928
2022
Q2 		$21K Hold
18,200
– – ﹤0.01% 2927
2022
Q1 		$37K Hold
18,200
– – ﹤0.01% 2938
2021
Q4 		$52K Hold
18,200
– – ﹤0.01% 2924
2021
Q3 		$77K Sell
18,200
-5,400
-23% -$24.1K ﹤0.01% 2877
2021
Q2 		$125K Sell
23,600
-6,900
-23% -$33.2K ﹤0.01% 2814
2021
Q1 		$142K Hold
30,500
– – ﹤0.01% 2751
2020
Q4 		$101K Sell
30,500
-98,500
-76% -$374K ﹤0.01% 2625
2020
Q3 		$427K Hold
129,000
– – ﹤0.01% 2154
2020
Q2 		$435K Buy
129,000
+17,952
+16% +$84.9K ﹤0.01% 2101
2020
Q1 		$425K Buy
111,048
+41,300
+59% +$192K ﹤0.01% 2055
2019
Q4 		$421K Buy
69,748
+50,850
+269% +$348K ﹤0.01% 2216
2019
Q3 		$143K Sell
18,898
-21,294
-53% -$240K ﹤0.01% 2423
2019
Q2 		$545K Sell
40,192
-71,408
-64% -$824K ﹤0.01% 2080
2019
Q1 		$605K Buy
111,600
+70,400
+171% +$343K ﹤0.01% 2051
2018
Q4 		$122K Sell
41,200
-30,400
-42% -$166K ﹤0.01% 2475
2018
Q3 		$584K Buy
71,600
+13,400
+23% +$103K ﹤0.01% 2089
2018
Q2 		$567K Buy
58,200
+16,545
+40% +$170K ﹤0.01% 2080
2018
Q1 		$362K Buy
41,655
+23
+0.1% +$248 ﹤0.01% 2209
2017
Q4 		$521K Buy
+41,632
New +$477K ﹤0.01% 2079

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

T. Rowe Price Associates's ZYNE Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 18,200 shares — an estimated $14K sold.

T. Rowe Price Associates first reported a position in ZYNE in Q4 2017 and held it in 20 quarters. The position peaked at $605K in Q1 2019. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 18,200 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $14K.
  • T. Rowe Price Associates first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 20 quarters.
  • T. Rowe Price Associates's Zynerba Pharmaceuticals, Inc position peaked at $605K in Q1 2019.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.